

LORVAS

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only

Abbreviated Prescribing information for **LORVAS** [Indapamide 2.5mg Tablets] [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Indapamide exerts its action in the control of hypertension is not completely elucidated: both renal and extra renal actions may be involved. The extra renal actions involve improvement in arterial compliance and a reduction in arteriolar and total peripheral resistance through: a reduction in the contractility of vascular smooth muscle due to a modification of transmembrane ion exchanges, essentially calcium; vasodilatation due to stimulation of the synthesis of prostaglandin PGE₂ and the vasodilator and platelet antiaggregant prostacyclin PGI₂; potentiation of the vasodilator action of bradykinin.

INDICATION: For treatment of mild to moderate hypertension.

DOSAGE AND ADMINISTRATION: The dosage is one tablet 2.5mg indapamide, daily to be taken in the morning.

CONTRAINDICATION: Contraindicated in patients with hypersensitivity to indapamide, to other sulfonamides or to any of the excipients, severe renal failure, anuria, hepatic encephalopathy or severe impairment of liver function, hypokalaemia and recent cerebrovascular accident.

WARNINGS & PRECAUTIONS: Use cautiously or stop the indapamide in patient with impaired liver function, photosensitivity, allergic to excipients, water and electrolyte imbalance, long QT interval, hypokalaemia, bradycardia, severe arrhythmias, fatal torsades de pointes, hypercalcaemia, hyperuricaemic patients, hypovolaemia, in athletes.

DRUG INTERACTIONS: Class Ia antiarrhythmics (quinidine, hydroquinidine, disopyramide), class III antiarrhythmics (amiodarone, sotalol, dofetilide, ibutilide), chlorpromazine, cyamemazine, levomepromazine, thioridazine, trifluoperazine, amisulpride, sulpiride, sultopride, tiapride, droperidol, haloperidol, bepridil, cisapride, diphemanil, erythromycin IV, halofantrine, mizolastine, pentamidine, sparfloxacin, moxifloxacin, vincamine IV, NSAIDs, ACE inhibitors, amphotericin B (IV), gluco- and mineralo-corticoids (systemic route), tetracosactide, stimulant laxatives, baclofen, digitalis preparations, metformin, Iodinated contrast media, antidepressants, neuroleptics, calcium (salts), ciclosporin, and tacrolimus.

ADVERSE REACTIONS: Nausea, constipation, dry mouth, gastric irritation, maculopapular rashes, purpura, hives, pruritus, erythema multiforme, epidermal necrolysis, vasculitis, cough, rhinitis, pharyngitis, sinusitis, conjunctivitis, vomiting, abnormal hepatic function, vertigo, fatigue, headache, paraesthesia, lightheadedness, drowsiness, renal failure, increased serum urea nitrogen, or creatinine, angioneurotic oedema and/or urticaria, toxic epidermic necrolysis, steven Johnson syndrome and bullous eruption.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

IN/ LORVAS 2.5mg/Aug-2015/01/ABPI

(Additional information is available on request)